23. The number of observations included in each model was determined by the variable with the smallest number of observations: since patient numbers declined as the study progressed, the models that included C3;D28 data, for example, comprised far fewer observations than the biomarker subset overall. Supplementary Fig. S1 . Study design. Supplementary Fig. S2 . Patient disposition and flow throughout the study. PP, per-protocol population. *These patients never received blinded treatment due to study unblinding. Supplementary Fig. S3 . Treatment histories of individual patients randomized to placebo. Supplementary Fig. S4 . Effect of treatment on circulating biomarker levels relative to baseline (C1;D1). *P < 0.0001, † P = 0.0001 versus baseline (Wilcoxon signed-rank [two-tailed] 
test).
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